About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Boston | 559 Studies

Clinical Trials LymphomaBoston

Lymphoma Clinical Trials in Boston

Find 559 clinical trials for lymphoma near Boston, Massachusetts. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Boston

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 21-40 of 559 trials

TerminatedRituximab + Immunotherapy in Follicular LymphomaThis research study is studying several new investigational drug combinations as a possible treatment for follicular lymphoma.NCT03636503·Duarte, California and 5 others CompletedA Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) PatientsThis study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers.NCT01262235·Scottsdale, Arizona and 7 others CompletedSafety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative ColitisTo assess clinical response to MMX mesalamine/mesalazine between a low and high dose in children and adolescents aged 5-17 years with mild to moderate Ulcerative Colitis (UC) or…NCT02093663·Baltimore, Maryland and 32 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

RecruitingRituximab Plus Venetoclax in Front Line Marginal Zone LymphomaThe purpose of this study is to see if the combination of rituximab and venetoclax is effective in treating participants with untreated Marginal Zone Lymphoma (MZL).NCT06510309·Boston, Massachusetts

CompletedPomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular LymphomaThis phase I trial studies the side effects and best dose of pomalidomide when given together with dexamethasone in treating patients with primary central nervous system lymphoma…NCT01722305·Scottsdale, Arizona and 6 others

CompletedY 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's LymphomaRATIONALE: Monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan and rituximab, can locate cancer cells and either kill them or deliver radioactive cancer-killing…NCT00073957·Boston, Massachusetts and 1 other

CompletedA Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced CancerPF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells.NCT00585195·Orange, California and 28 others

CompletedA Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque PsoriasisThis study is designed to provide efficacy and safety data of several doses of AEB071 so that the optimal dose and treatment duration can be chosen for testing in later studies in…NCT00885196·Hot Springs, Arizona and 39 others

Active not recruitingBlinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaThis phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+…NCT02879695·New Haven, Connecticut and 6 others

RecruitingTegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsThis phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or…NCT04851119·Birmingham, Alabama and 20 others

CompletedA Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesThis is a global, open-label, multi-arm, parallel multi-cohort, multi-center, Phase 1/2 study to determine the safety, tolerability, PK, efficacy and patient-reported quality of…NCT03310619·Duarte, California and 8 others

CompletedMK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaThis phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or…NCT01231919·Birmingham, Alabama and 24 others

CompletedVorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaThis phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating young patients with refractory or recurrent solid…NCT00994500·Chicago, Illinois and 5 others

Active not recruitingEvolut™ EXPAND TAVR II Pivotal TrialObtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.NCT05149755·Birmingham, Alabama and 93 others

CompletedAdaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell…NCT06004167·Boston, Massachusetts and 1 other

RecruitingA Master Protocol to Evaluate the Long-Term Safety of (LY3527727) PirtobrutinibThe master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies…NCT06876649·Jacksonville, Florida and 37 others

CompletedEscalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaThe purpose of this study is to evaluate the safety and tolerability of AVL-292 as monotherapy in subjects with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), chronic…NCT01351935·Huntsville, Alabama and 12 others

Active not recruitingEXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity StrategyThis study is a multi-site, cluster randomized, two group implementation trial comparing a low- versus high-intensity implementation strategy for supporting hospital-based opioid…NCT04921787·Boston, Massachusetts and 3 others

CompletedA Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's LymphomaThis is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0980 administered to patients with…NCT00854126·Boston, Massachusetts and 2 others

SuspendedA Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCLThis is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma.NCT05138458·Duarte, California and 5 others

PreviousPage 2 of 28Next

Other Conditions in Boston

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia